ProQR Therapeutics N.V.
PRQR
$1.92
$0.073.78%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
8/15/2026
-
Simply Wall St
8/15/2026
-
MarketBeat
8/14/2026
-
Zacks Investment Research
8/13/2026
-
TipRanks
8/13/2026
-
Globe Newswire
8/4/2026
-
MarketBeat
7/21/2026
-
MarketBeat
7/17/2026
-
The Cerbat Gem
7/13/2026
-
MarketBeat
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages
7/10/2026
-
MarketBeat
7/6/2026
-
TipRanks: TheFly
7/4/2026
-
Seeking Alpha - Long Ideas
7/4/2026
-
Seeking Alpha - Healthcare
7/2/2026
-
Simply Wall St
7/2/2026
-
The Cerbat Gem
6/29/2026
-
The Cerbat Gem
6/26/2026
-
TipRanks: TheFly
6/26/2026
-
TipRanks: TheFly
6/26/2026
-
TipRanks: TheFly
6/25/2026
-
Benzinga
6/25/2026
-
TipRanks: TheFly
6/25/2026
-
TipRanks: TheFly
6/25/2026
-
Globe Newswire
6/25/2026
-
Globe Newswire
6/2/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, May 12, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
31 88 166 7000
Address
Zernikedreef 9
Leiden, 2333 CK
Leiden, 2333 CK
Country
Year Founded
Business Description
Sector
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its...
more